Sees FY25 gross margin 73%-75%. Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized leader in drug-resistant epilepsy therapy and fully develop the potential of the RNS System. To this end, the Company is focused on achieving the following three-year strategic objectives: 20%+ revenue CAGR; Indication expansion to include Idiopathic Generalized and Pediatric drug-resistant epilepsy patients; Become the neuromodulation category leader in efficiency and ease of use with AI Tools and Remote Programming; Significantly expand patient and referral awareness and access through direct-to-consumer campaigns and Project CARE; Achieve cash flow break even.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.